试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-21
Mapping Draining Lymph Nodes in CNS Malignancies
编号:NCT04096716登记状态:提前终止企业 / 申办者:Washington University School of Medicine
药物 / 成分:Tc-99m tilmanocept
登记的停止原因(原文):Insufficient funding/staff
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-21
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
编号:NCT04267939登记状态:提前终止企业 / 申办者:Bayer
药物 / 成分:Elimusertib (BAY1895344)、Niraparib
登记的停止原因(原文):There was no anticipated benefit of the experimental combination as tested over available standard therapies; therefore Sponsor has decided to terminate the investigation.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-21
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
编号:NCT04425629登记状态:提前终止企业 / 申办者:Regeneron Pharmaceuticals
药物 / 成分:casirivimab+imdevimab combination therapy
登记的停止原因(原文):Emerging SARS-CoV-2 variants impacting susceptibility to study drug
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-21
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
编号:NCT04498377登记状态:提前终止企业 / 申办者:EVIVE Biotechnology
药物 / 成分:F-652、Placebo
登记的停止原因(原文):There have been significant changes in the FDA guidelines and clinical standard of care
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-21
Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL
编号:NCT04803123登记状态:提前终止企业 / 申办者:Dorothy Sipkins, MD, PhD
药物 / 成分:Copanlisib
登记的停止原因(原文):Sponsor halted clinical development of study drug
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-21
A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia
编号:NCT04836494登记状态:提前终止企业 / 申办者:CoA Therapeutics, Inc., a BridgeBio company
药物 / 成分:BBP-671、Placebo、BBP-671
登记的停止原因(原文):Slow recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-21
Study of EQU-001 for Uncontrolled Focal Onset Seizures
编号:NCT05473442登记状态:提前终止企业 / 申办者:Equilibre Biopharmaceuticals B.V.
药物 / 成分:EQU-001、Matching Placebo
登记的停止原因(原文):insufficient funding to complete the study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-21
Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer
编号:NCT05932667登记状态:提前终止企业 / 申办者:Institut Curie
药物 / 成分:Milademetan、Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)
登记的停止原因(原文):Financial partner providing study drug could no longer support the trial
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-20
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
编号:NCT00920582登记状态:提前终止企业 / 申办者:MacroGenics
药物 / 成分:Teplizumab Herold Regimen、Placebo、Teplizumab 33.3% Herold Regimen、Teplizumab Curtailed Herold Regimen
登记的停止原因(原文):Business decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-20
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
编号:NCT04634825登记状态:提前终止企业 / 申办者:MacroGenics
药物 / 成分:Enoblituzumab、Retifanlimab、Tebotelimab
登记的停止原因(原文):Based on internal review of safety data
查看官方原始记录 ↗